The effect of Zataria in the treatment of chronic obstructive pulmonary disease

The effect of hydro – alcoholic extracts of Zataria multiflora on patients with chronic obstructive pulmonary disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016112729191N2

Enrollment

Registered

2017-01-07

Start date

2016-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease. Other chronic obstructive pulmonary disease

Interventions

Intervention 1: Hydro – alcoholic extracts of Zataria multiflora, 5 mg/kg daily as oral syrup (made by the Faculty of Pharmacy, Mashhad University of Medical Sciences), three times a day for two month

Treatment - Drugs

Hydro – alcoholic extracts of Zataria multiflora, 5 mg/kg daily as oral syrup (made by the Faculty of Pharmacy, Mashhad University of Medical Sciences), three times a day for two months

Hydro – alcoholic extracts of Zataria multiflora, 10 mg/kg daily as oral syrup (made by the Faculty of Pharmacy, Mashhad University of Medical Sciences), three times a day for two months

Placebo daily as oral syrup (made by the Faculty of Pharmacy, Mashhad University of Medical Sciences), three times a day for two months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease based on spirometry test; clinical symptoms Exclusion criteria: Having other lung diseases; cardiovascular diseases; chronic inflammatory diseases; acute infections; malignancies; autoimmune diseases; immunodeficiency

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Evaluation of clinical symptoms including cough, breathlessness, wheeze. Timepoint: Before the intervention, one month after the start of intervention and the end of two months. Method of measurement: Standard questionare.;Wheezing rate. Timepoint: Before the intervention, one month after the start of intervention and the end of two months. Method of measurement: Chest auscultation.;Lung function tests. Timepoint: Before the intervention, one month after the start of intervention and the end of two months. Method of measurement: Spirometry.;Inflammatory mediators in blood serum and sputum. Timepoint: Before the intervention, one month after the start of intervention and the end of two months. Method of measurement: Standard kits.	—

Measure

Time frame

Evaluation of clinical symptoms including cough, breathlessness, wheeze. Timepoint: Before the intervention, one month after the start of intervention and the end of two months. Method of measurement: Standard questionare.;Wheezing rate. Timepoint: Before the intervention, one month after the start of intervention and the end of two months. Method of measurement: Chest auscultation.;Lung function tests. Timepoint: Before the intervention, one month after the start of intervention and the end of two months. Method of measurement: Spirometry.;Inflammatory mediators in blood serum and sputum. Timepoint: Before the intervention, one month after the start of intervention and the end of two months. Method of measurement: Standard kits.

—

Secondary

Measure	Time frame
-. Timepoint: -. Method of measurement: -.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahideh Ghorani Sirjani

Mashhad University of Medical Sciences

Ghoranisv921@mums.ac.ir+98 51 3882 8888

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026